

Genetically Modified Mosquitoes

Why in news?

 $n\n$

The Department of Biotechnology (DBT) is hesitant to permit field trials to release GM mosquitoes to tackle certain diseases.

 $n\n$

What is the initiative?

 $n\n$

\n

 Aedes aegypti mosquito is the carrier of diseases such as Zika, dengue and chikungunya.

• A new initiative thus aims at reducing the population of Aedes aegypti mosquito.

• It comes from the Mumbai-based company, Gangabishan Bhikulal Investment and Trading Limited (GBIT).

\n

 $n\n$

What is the new gene?

 $n\n$

• Diseases such as Zika, dengue and chikungunya are transmitted when an infected, pregnant female mosquito bites somebody.

Males do not bite and are, therefore, harmless.

• So GBIT wants to introduce a new Genetically Modified (GM) male Aedes aegypti mosquito.

• This GM insect has been bred by Oxitec, an R&D biotech company with roots in the University of Oxford.

\n

- Oxitec has bio-engineered a $transgenic\ male\ Aedes\ aegypti\ mosquito.$

 $n\n$

What does it do?

 $n\n$


\n

• The idea is to release a large number of such GM male mosquitoes into the trial zone.

\n

- These will then breed with normal females in the wild.
- \bullet In the next generation, only the males would survive and these would breed again, with normal females. $\mbox{\sc h}$
- \bullet After a few generations, the female population will be drastically reduced. $\ensuremath{\backslash n}$
- \bullet Eventually this cycle will result in a reduction of the entire mosquito population. $\ensuremath{\backslash n}$

 $n\n$



 $n\n$

How is it justified?

 $n\n$

\n

• The life cycle of a mosquito is only around two-three weeks.

• So the effects of the trial should be apparent in a few months.

• Transgenic males do not bite and the modified genes are said to be harmless to humans.

\n

• The so-called "Friendly Aedes" project launched "closed cage" trials at the Oxitec facility in Maharashtra.

\n

• Trials have been launched in Malaysia, Brazil, and Florida as well.

• Given these, permission has now been sought for open field trials in India.

 $n\n$

Why is DBT hesitant to approve?

 $n\n$

\n

• Indian policy has been very cautious about allowing the genetically modified technologies.

\n

• DBT scientists fear that there may be unknown hazards associated with large scale trials.

۱'n

• It is thus feared that it could result in harmful consequences to the environment or ecology.

\n

• Notably, the Aedes aegypti is part of the food chain.

n

• During its life cycle, it is consumed by fishes.

\n

• Also, during its early aquatic phase, it is consumed by frogs and then by birds, lizards and spiders.

\n

 A drastic reduction in the mosquito population could thus impact prey species.

۱n

• This could also potentially result in ecological collapse.

۱n

• There is also a possibility that the engineered genes could directly harm the species that consume mosquitoes.

\n

• More research may be required to ensure that there are no unforeseen consequences.

\n

 $n\n$

 $n\n$

Source: Business Standard

\n

